ClinicalTrials.gg
CompletedNCT04803734Updated Mar 18, 2024Results posted

Bioequivalence Between Albuterol Sulfate Inhalation Aerosol 108 mcg Per Actuation and Proair HFA (Albuterol Sulfate) Inhalation Aerosol 90 mcg Per Actuation in Healthy Volunteers Under Fasting Conditions

An interventional study of Albuterol Sulfate inhalation aerosol 108mcg per actuation and Proair HFA (albuterol sulfate) Inhalation Aerosol 90 mcg per actuation in Healthy, sponsored by Intech Biopharm Ltd.. Completed at 1 site in Taiwan. Open to participants aged 20 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-18.

Sponsored by Intech Biopharm Ltd. · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
20 Years to 60 Years
Sex
All
01

Study summary

This study was designed to assess the bioequivalence between the test products (Albuterol Sulfate Inhalation Aerosol 108 mcg Per Actuation) and the reference products (Proair HFA [Albuterol Sulfate] Inhalation Aerosol 90 mcg Per Actuation) in healthy volunteers under fasting conditions. The test product was considered bioequivalent to the reference product if the T/R ln-transformed AUC(0-t), AUC(0-inf), and Cmax were within 80.00-125.00% of those of the reference.

Read the detailed description

A single-dose, randomized, open-label, two-period, two-sequence, two-treatment, single-centre, crossover bioequivalence study was carried out under fasting conditions in healthy adults, aged 20-60 years. For each period, each subject received a single dose as equivalent to 180 mcg of albuterol of the study drugs according to the pre-determined randomization scheme. Each subject was drawn 22 times over the period of 24 hours. Plasma samples were collected and analyzed for albuterol concentrations by using LC-MS/MS. For each subject, there were 2 dosing periods separated by a 14-day washout period. During the study, standardized meals were provided to all subjects while institutionalized.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Intech Biopharm Ltd. is the lead sponsor of 11 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female volunteers, aged 20-60, inclusive.
  2. of 18.0-30.0 kg/m², inclusive. The body weight should be over 50 kg, inclusive. (BMI will be calculated as weight in kilogram [kg]/height in meters² [m²]).
  3. Healthy or Non Clinical Significant, according to the medical history, , chest X-ray and physical examination as determined by the Principal Investigator/Sub-Investigator.
  4. Systolic blood pressure between 90-139 mmHg, inclusive, and diastolic blood pressure between 50-90 mmHg, inclusive, and pulse rate between 50-100 bpm, inclusive and temperature between 35.0-37.4℃.
  5. Screening laboratory values within reference range or NCS as determined by the Principal Investigator/Sub-Investigator.
  6. Ability to comprehend and be informed of the nature of the study, as assessed by clinical staff. Capable of giving written prior to receiving any study medication. Must be able to communicate effectively with clinical staff.
  7. Willing to fast for at least 14 hours and to consume standard meals.
  8. Availability to volunteer for the entire study duration and willing to adhere to all protocol requirements.
  9. Agree not to have a tattoo, body piercing, or other any invasive procedure and blood donation until the end of the study.
  10. Never-smokers; or former smokers who have smoked ≥ 100 cigarettes in their lifetime and have not consumed any tobacco or tobacco containing products for at least 12 months prior to screening.
  11. Subjects who are non-asthmatic, defined as no clinical history of asthma, allergy or atopy.
  12. Able to perform special breathing using nebulizer correctly as per the required standard.
  13. Subjects must fulfill at least one of the following:

    • Be surgically sterile for a minimum of 6 months;
    • for a minimum of 1 year;
    • Agree to avoid pregnancy and use medically acceptable method of from screening day until 30 days after the study ends (last study procedure).

Exclusion criteria

Exclusion Criteria:

  1. Known history or presence of any hepatic (e.g. active liver disease, hepatic impairment), renal/genitourinary (e.g. renal impairment), gastrointestinal, cardiovascular, cerebrovascular, pulmonary, endocrine (e.g. hypothyroidism), immunological, musculoskeletal (e.g. myopathy, rhabdomyolysis), neurological, psychiatric, dermatological, hematological disease, or any other medical conditions, unless determined as not clinically significant by the Principal Investigator/Sub-Investigator.
  2. Presence of any clinically significant illness within 30 days prior to first dosing, as determined by the Principal Investigator/Sub-Investigator.
  3. Presence of any significant physical or organ abnormality as determined by the Principal Investigator/Sub-Investigator.
  4. A positive test result for any of the following: , surface antigen, , drugs of abuse (amphetamines, barbiturates, benzodiazepines, cocaine, opiates, phencyclidine, tetrahydrocannabinol), breath alcohol test. Positive pregnancy test for female subjects.
  5. Known history or presence of:

    • Alcohol abuse within one year prior to first drug administration;
    • Drug abuse or dependence;
    • or idiosyncratic reaction to albuterol, its , and/or related substances;
    • Allergy to standardized meal provided by site and/or presence of any dietary restrictions;
  6. Intolerance to and/or difficulty in blood sampling through venipuncture.
  7. Abnormal diet patterns (for any reason) during the 4 weeks preceding the study, including fasting, high protein diets etc.
  8. Except for screening procedures, blood donation that results in blood loss of not more than 250 ml in the past 2 months prior to first dosing; blood loss of more than 250 ml within 3 months prior to first dosing.
  9. Donation of plasma by plasmapheresis within 7 days prior to first drug administration.
  10. Individuals who receives an drug from 2 months prior to first drug administration.
  11. Consumption of products containing caffeine/methylxanthines, poppy seeds and/or alcohol within 48 hours before dosing and products containing grapefruit and/or pomelo (shown to inhibit cytochrome P450 [CYP] 3A4 activity) within 10 days prior to first drug administration.
  12. Use of any medication, including oral multivitamins, herbal and/or dietary supplements within 30 days prior to first drug administration (except topical agents without systemic absorption as determined by the Principal Investigator/Sub-Investigator).
  13. Females taking oral or transdermal hormonal within 30 days prior to first drug administration.
  14. Females having used implanted, injected, intravaginal, or intrauterine hormonal contraceptive within 6 months prior to first drug administration.
  15. Individuals having undergone any major surgery within 6 months prior to the start of the study, unless deemed otherwise by Principal Investigator/Sub-Investigator.
  16. Using tobacco products, nicotine products (patches, gum etc.) within 6 months prior to first drug administration.
  17. Lactating women.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Test Group

    Albuterol Sulfate inhalation aerosol

    Drug: Albuterol Sulfate inhalation aerosol 108mcg per actuation

  • Active comparator
    Reference Group

    Proair HFA (albuterol sulfate) Inhalation Aerosol

    Drug: Proair HFA (albuterol sulfate) Inhalation Aerosol 90 mcg per actuation

Interventions

  • DrugAlbuterolStudies of AlbuterolAlbuterol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    MDI, 2 puffs, single dose, fasting

    Also known as: Albuterol 90mcg/puff

  • DrugAlbuterolStudies of AlbuterolAlbuterol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    MDI, 2 puffs, single dose, fasting

    Also known as: Albuterol 90mcg/puff

06

What researchers measure

Primary outcomes

  1. Cmax

    The maximal observed plasma concentration of Albuterol Sulfate.

    Time frame: 0 hour (pre-dose), as well as at 2, 5, 10, 15, 20, 30, 45 minutes, and 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 4, 6, 8, 12, 16 and 24 hours post-dose

  2. AUC(0-t)

    Area under the concentration time curve from time zero until the last measurable concentration or last sampling time t, whichever occurs first.

    Time frame: 0 hour (pre-dose), as well as at 2, 5, 10, 15, 20, 30, 45 minutes, and 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 4, 6, 8, 12, 16 and 24 hours post-dose

  3. AUC(0-inf)

    Area under the concentration time curve from time zero to infinity.

    Time frame: 0 hour (pre-dose), as well as at 2, 5, 10, 15, 20, 30, 45 minutes, and 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 4, 6, 8, 12, 16 and 24 hours post-dose

Secondary outcomes

  1. Tmax

    Time when the maximal plasma concentration is observed.

    Time frame: 0-24 hours

  2. T1/2

    Terminal elimination half-life, estimated as ln(2)/λ.

    Time frame: 0-24 hours

  3. Kel(λ)

    Terminal elimination rate constant, estimated by linear regression analysis of the terminal portion of the ln-concentration vs. time plot.

    Time frame: 0-24 hours

  4. Mean Residence Time (MRT)

    Mean residence time (MRT) is calculated by the area under the first moment curve dividing by area under the concentration time curve.

    Time frame: 0-24 hours

07

Results

Posted Sep 25, 2023

Participant flow

Eighty-four subjects were recruited and screened for the eligibility.

Participant flow — Overall Study
MilestoneAlbuterol Sulfate Inhalation Aerosol First, Then ProairHFA (Albuterol Sulfate) Inhalation AerosolProair HFA (Albuterol Sulfate) Inhalation Aerosol First, Then Albuterol Sulfate Inhalation Aerosol
Started3030
Completed3028
Not completed02
Withdrew: Withdrawal by subject01
Withdrew: Protocol violation01

Outcome measures

PrimaryCmax

The maximal observed plasma concentration of Albuterol Sulfate.

Time frame:
0 hour (pre-dose), as well as at 2, 5, 10, 15, 20, 30, 45 minutes, and 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 4, 6, 8, 12, 16 and 24 hours post-dose
Reported as:
Mean · pg/mL
Cmax
pg/mLAlbuterol Sulfate Inhalation AerosolProair HFA (Albuterol Sulfate) Inhalation Aerosol
Cmax812.477 ± 281.148945.456 ± 359.695
Statistical analysis
  • Albuterol Sulfate Inhalation Aerosol vs Proair HFA (Albuterol Sulfate) Inhalation Aerosol · ANOVA · p = 0.0328 · Ratio of geometric least square mean: 0.862 · 90% CI 0.807 to 0.922
PrimaryAUC(0-t)

Area under the concentration time curve from time zero until the last measurable concentration or last sampling time t, whichever occurs first.

Time frame:
0 hour (pre-dose), as well as at 2, 5, 10, 15, 20, 30, 45 minutes, and 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 4, 6, 8, 12, 16 and 24 hours post-dose
Reported as:
Mean · hr*pg/mL
AUC(0-t)
hr*pg/mLAlbuterol Sulfate Inhalation AerosolProair HFA (Albuterol Sulfate) Inhalation Aerosol
AUC(0-t)4806.319 ± 981.4775090.449 ± 1053.602
Statistical analysis
  • Albuterol Sulfate Inhalation Aerosol vs Proair HFA (Albuterol Sulfate) Inhalation Aerosol · ANOVA · p = <0.0001 · Ratio of geometric least square mean: 0.941 · 90% CI 0.909 to 0.976
PrimaryAUC(0-inf)

Area under the concentration time curve from time zero to infinity.

Time frame:
0 hour (pre-dose), as well as at 2, 5, 10, 15, 20, 30, 45 minutes, and 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 4, 6, 8, 12, 16 and 24 hours post-dose
Reported as:
Mean · hr*pg/mL
AUC(0-inf)
hr*pg/mLAlbuterol Sulfate Inhalation AerosolProair HFA (Albuterol Sulfate) Inhalation Aerosol
AUC(0-inf)5204.806 ± 1081.8625509.006 ± 1148.747
Statistical analysis
  • Albuterol Sulfate Inhalation Aerosol vs Proair HFA (Albuterol Sulfate) Inhalation Aerosol · ANOVA · p = <0.0001 · Ratio of geometric least square mean: 0.942 · 90% CI 0.910 to 0.975
SecondaryTmax

Time when the maximal plasma concentration is observed.

Time frame:
0-24 hours
Reported as:
Mean · hr
Tmax
hrAlbuterol Sulfate Inhalation AerosolProair HFA (Albuterol Sulfate) Inhalation Aerosol
Tmax0.929 ± 1.0890.514 ± 0.529
SecondaryT1/2

Terminal elimination half-life, estimated as ln(2)/λ.

Time frame:
0-24 hours
Reported as:
Mean · hr
T1/2
hrAlbuterol Sulfate Inhalation AerosolProair HFA (Albuterol Sulfate) Inhalation Aerosol
T1/26.928 ± 1.1656.985 ± 1.357
SecondaryKel(λ)

Terminal elimination rate constant, estimated by linear regression analysis of the terminal portion of the ln-concentration vs. time plot.

Time frame:
0-24 hours
Reported as:
Mean · 1/hr
Kel(λ)
1/hrAlbuterol Sulfate Inhalation AerosolProair HFA (Albuterol Sulfate) Inhalation Aerosol
Kel(λ)0.103 ± 0.0190.103 ± 0.021
SecondaryMean Residence Time (MRT)

Mean residence time (MRT) is calculated by the area under the first moment curve dividing by area under the concentration time curve.

Time frame:
0-24 hours
Reported as:
Mean · hr
Mean Residence Time (MRT)
hrAlbuterol Sulfate Inhalation AerosolProair HFA (Albuterol Sulfate) Inhalation Aerosol
Mean Residence Time (MRT)8.629 ± 1.2028.474 ± 1.455

Adverse events

Collected over Approximately 16 days for each subject.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Test Group0/60 (0%)0/60 (0%)4/60 (6.7%)
Reference Group0/58 (0%)0/58 (0%)1/58 (1.7%)
Most frequent other events
Most frequent other events
EventTest GroupReference Group
HypertriglyceridemiaMetabolism and nutrition disorders0/601/58
Throat infectionInfections and infestations1/600/58
Aspartate aminotransferase (AST) increasedInvestigations1/600/58
Creatinine increasedInvestigations1/600/58
Alanine aminotransferase (ALT) increasedInvestigations1/600/58

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Study Participants
Mean31.9 ± 7.4
Sex: Female, Male
Sex: Female, Male(Participants)All Study Participants
Female19
Male41
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Study Participants
American Indian or Alaska Native0
Asian60
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Height
Height(cm)All Study Participants
Mean167.8 ± 6.8
Weight
Weight(kg)All Study Participants
Mean65.5 ± 8.6
Body mass index (BMI)
Body mass index (BMI)(kg/m^2)All Study Participants
Mean23.2 ± 2.2
08

Study locations

1 site
  • Tamshui Mackay Memorial Hospital
    New Taipei City, 251, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in May 2021, 1 month.

Results were first posted in Sep 2023, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2021
First posted
Mar 18, 2021
StartActual
Mar 19, 2021
Primary completionActual
May 10, 2021
CompletionActual
May 14, 2021
Results first posted
Sep 25, 2023
Last update
Mar 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04803734
Lead sponsor
Intech Biopharm Ltd.
Responsible party
Sponsor
First posted
Mar 18, 2021
Start date
Mar 19, 2021
Primary completion
May 10, 2021
Completion
May 14, 2021
Results posted
Sep 25, 2023
Last update
Mar 18, 2024

Study contacts

Wen-Kuei Chang, MD
principal investigator · Tamshui Mackay Memorial Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albuterol

Start the discussion